12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety)

Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety)

Mood and anxiety disorders represent the most prevalent psychiatric conditions encountered in Canadian ambulatory and institutional pharmacy practice. Pharmacists play a central role in screening, therapeutic agent selection, dosing optimization, adverse effect management, and longitudinal monitoring. The clinical management of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Panic Disorder is guided in Canada primarily by evidence-based consensus recommendations published by the Canadian Network for Mood and Anxiety Treatments (CANMAT).

---

Diagnostic Criteria for Major Depressive Disorder (DSM-5 & CANMAT)

Under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), a diagnosis of Major Depressive Disorder requires the presence of at least 5 out of 9 diagnostic symptoms during the same 2-week period, representing a clear change from previous functioning. Crucially, at least one of the symptoms must be either:

1. Depressed mood most of the day, nearly every day; OR
2. Markedly diminished interest or pleasure (anhedonia) in all, or almost all, activities most of the day, nearly every day.

The SIGECAPS Mnemonic Framework

To systematically evaluate the nine DSM-5 diagnostic criteria for MDD, clinicians utilize the SIGECAPS mnemonic:

                           DSM-5 MDD DIAGNOSTIC CRITERIA (SIGECAPS)

   S ── Sleep Disturbance (Insomnia [initial, middle, terminal] or Hypersomnia)
   I ── Interest Diminished (Marked anhedonia in activities previously enjoyed) [Cardinal 1]
   G ── Guilt or Worthlessness (Excessive, inappropriate, or delusional feelings)
   E ── Energy Loss (Persistent fatigue, lethargy, physical exhaustion without exertion)
   C ── Concentration Impaired (Indecisiveness, executive dysfunction, subjective brain fog)
   A ── Appetite / Weight Changes (Significant unintentional weight loss/gain > 5% in a month)
   P ── Psychomotor Agitation or Retardation (Observable by others, not merely subjective)
   S ── Suicidal Ideation (Recurrent thoughts of death, passive ideation, active plans/attempts)
   [+ Depressed Mood most of the day, nearly every day]                       [Cardinal 2]

   Diagnostic Threshold: ≥ 5 of 9 symptoms for ≥ 2 weeks (must include Depressed Mood or Anhedonia)

Medical and Substance Rule-Outs

Before confirming MDD and initiating pharmacotherapy, clinicians must rule out organic secondary causes and substance-induced etiologies:

• Endocrine Disorders: Hypothyroidism (screen serum Thyroid Stimulating Hormone [TSH]), Cushing syndrome, Addison disease, uncontrolled diabetes mellitus.
• Nutritional Deficiencies: Vitamin B12 deficiency (pernicious anemia or malabsorption), folate deficiency, severe iron deficiency anemia (ferritin).
• Neurological Conditions: Multiple sclerosis, Parkinson disease, post-stroke depression, early cognitive impairment / dementia.
• Medication-Induced Depressive Symptoms: Corticosteroids, systemic interferon-alpha, isotretinoin, varenicline, beta-blockers (propranolol), and chronic opioid or sedative-hypnotic abuse/withdrawal.

---

CANMAT Clinical Guidelines: First-Line Antidepressant Classes

CANMAT clinical guidelines establish five primary classes of first-line antidepressants for the acute treatment of MDD in adults based on Level 1 clinical trial evidence: SSRIs, SNRIs, NDRIs, NaSSAs, and multimodal agents.

                         CANMAT FIRST-LINE ANTIDEPRESSANTS
                                         │
         ┌───────────────────────────────┼───────────────────────────────┐
         ▼                               ▼                               ▼
   SEROTONERGIC                    DUAL ACTION                     NORADRENERGIC /
   MONOTHERAPY                  (SEROTONIN + NE)                      MULTIMODAL
• SSRIs:                        • SNRIs:                        • NDRI: Bupropion XL
  - Escitalopram (10–20 mg)       - Venlafaxine XR (75–225 mg)    - Activating, no sexual dysfunction
  - Sertraline (50–200 mg)        - Duloxetine (30–60 mg)       • NaSSA: Mirtazapine (15–45 mg)
  - Citalopram (20–40 mg)*        - Desvenlafaxine (50–100 mg)    - Sedating, appetite stimulating
  - Fluoxetine (20–60 mg)                                       • Multimodal: Vortioxetine (10–20 mg)
  - Paroxetine (20–50 mg)                                         - Cognitive symptom benefits
  - Fluvoxamine (100–300 mg)

  *Citalopram max 20 mg/day in age ≥ 65 or CYP2C19 poor metabolizers due to QTc prolongation.

1. Selective Serotonin Reuptake Inhibitors (SSRIs)

• Agents: Escitalopram (10–20 mg/day), Sertraline (50–200 mg/day), Citalopram (20–40 mg/day), Fluoxetine (20–60 mg/day), Paroxetine (20–50 mg/day), Fluvoxamine (100–300 mg/day).
• Mechanism: Selectively inhibit the presynaptic serotonin reuptake transporter (SERT / SLC6A4), increasing synaptic serotonin (5-HT) availability and down-regulating inhibitory 5-HT1A somatodendritic autoreceptors over time.
• Adverse Effects: Nausea, diarrhea, loose stools (especially sertraline via gut 5-HT3 and 5-HT4 receptors), insomnia, initial anxiety, headache, sexual dysfunction (anorgasmia, delayed ejaculation, erectile dysfunction occurring in 30% to 50% of patients), SIADH / hyponatremia (especially in elderly patients on thiazides), and mild antiplatelet effects (serotonin depletion in platelets; caution with NSAIDs, ASA, or anticoagulants).

2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

• Agents: Venlafaxine XR (75–225 mg/day), Duloxetine (30–60 mg/day, max 120 mg/day), Desvenlafaxine (50–100 mg/day).
• Mechanism: Inhibit reuptake of both serotonin (SERT) and norepinephrine (NET). At low doses (< 150 mg/day), venlafaxine acts predominantly as an SSRI; at moderate-to-high doses (≥ 150–225 mg/day), clinically significant norepinephrine reuptake inhibition emerges.
• Key Clinical Considerations:
  • Venlafaxine Blood Pressure Elevation: Noradrenergic stimulation can produce sustained, dose-dependent increases in resting diastolic and systolic blood pressure. Baseline and periodic blood pressure monitoring is mandatory.
  • Duloxetine Broad Indications & Hepatic Warnings: Approved for MDD, GAD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Duloxetine can increase serum transaminases and cause rare drug-induced liver injury; it is contraindicated in patients with hepatic impairment, end-stage renal disease (eGFR < 30 mL/min), or chronic heavy alcohol consumption.

3. Norepinephrine-Dopamine Reuptake Inhibitor (NDRI): Bupropion

• Agents: Bupropion XL (150–300 mg once daily, max 300 mg daily for depression; 450 mg daily for refractory cases), Bupropion SR (100–150 mg BID).
• Mechanism: Inhibits reuptake of dopamine (DAT) and norepinephrine (NET) without direct activity on serotonin reuptake.
• Distinct Clinical Advantages:
  • No Sexual Dysfunction: Does not stimulate 5-HT2A receptors; rate of sexual dysfunction is indistinguishable from placebo.
  • Weight Neutral or Mild Weight Loss: Does not cause weight gain; frequently produces modest appetite reduction.
  • Activating: Ideal for depression characterized by fatigue, hypersomnia, and executive apathy.
  • Lower Switch Rate: Exhibits lower rates of inducing mania in bipolar depression compared to SSRIs/SNRIs.
• Absolute Contraindications:
  • Seizure Disorders: Lowers seizure threshold in a dose-dependent fashion.
  • Eating Disorders (Active or Historical Bulimia Nervosa or Anorexia Nervosa): Electrolyte disturbances (purging, dehydration) combined with bupropion markedly increase the incidence of generalized grand mal seizures.
  • Abrupt Withdrawal of Alcohol, Benzodiazepines, or Antiepileptic Drugs: Dramatically elevates seizure risk.
  • Concurrent or Recent MAOI Use (within 14 days): Severe hypertensive crisis risk.

4. Noradrenergic and Specific Serotonergic Antidepressant (NaSSA): Mirtazapine

• Dosing: 15–45 mg once daily at bedtime.
• Mechanism: Antagonizes central presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, increasing release of both norepinephrine and serotonin. Additionally blocks post-synaptic 5-HT2 and 5-HT3 receptors, shunting 5-HT transmission specifically to 5-HT1A receptors.
• Clinical Profile:
  • Potent H1 Histamine Antagonism: At low doses (7.5–15 mg), mirtazapine exerts intense sedation and promotes marked appetite stimulation and weight gain. Ideal for depressed patients with severe insomnia, anorexia, and cachexia.
  • Inverse Sedation Paradox: At higher doses (30–45 mg), increased noradrenergic neurotransmission counteracts H1 antihistaminic sedation, often rendering the drug less sedating than at lower doses.
  • Zero Sexual Dysfunction & Antiemetic: 5-HT2 blockade prevents sexual dysfunction; 5-HT3 blockade prevents nausea.

5. Serotonin Multimodal Antidepressant: Vortioxetine

• Dosing: 10–20 mg once daily.
• Mechanism: Inhibits SERT, acts as a 5-HT1A agonist, 5-HT1B partial agonist, and 5-HT1D, 5-HT3, and 5-HT7 antagonist.
• Clinical Profile: Level 1 evidence demonstrating specific efficacy in improving cognitive dysfunction (attention, executive function, processing speed) in MDD. Very low incidence of sexual dysfunction or weight gain. Nausea is the most common adverse effect (up to 30%, usually mild and transient).

---

Therapeutic Trajectory & Treatment Phases

Successful pharmacotherapy of MDD requires understanding the timeline of response and maintaining treatment long enough to prevent recurrence.

                           CHRONOLOGICAL PHASES OF MDD THERAPY

     ACUTE PHASE (Weeks 1–8)           CONTINUATION PHASE (6–9 Months)         MAINTENANCE PHASE (≥ 2 Years)
┌─────────────────────────────────┐   ┌─────────────────────────────────┐   ┌─────────────────────────────────┐
│ • Goal: Complete Remission      │   │ • Goal: Prevent Relapse         │   │ • Goal: Prevent New Recurrence  │
│ • Week 2–4: Early response check│──►│ • Maintain FULL therapeutic dose│──►│ • Indicated for ≥ 3 episodes,   │
│   (≥ 20–25% symptom drop)       │   │   (do NOT decrease dose!)       │   │   severe suicidal risk, chronic │
│ • Week 4–8: Full adequate trial │   │ • Minimum 6–9 months duration   │   │   relapsing illness, or elderly │
└─────────────────────────────────┘   └─────────────────────────────────┘   └─────────────────────────────────┘

1. Acute Phase (Weeks 1 to 8)

• Therapeutic Trial Duration: An adequate trial of an antidepressant requires 4 to 8 weeks at a recognized therapeutic dose.
• Early Response Milestone (Weeks 2 to 4): A reduction in depressive symptoms of ≥ 20% to 25% on validated rating scales (e.g., PHQ-9, MADRS) within the first 2 to 4 weeks strongly predicts eventual clinical remission. If there is < 20% improvement at 4 weeks despite confirmed patient adherence and optimal dosing, CANMAT recommends switching to an alternate first-line antidepressant or adding an evidence-based adjunctive agent (e.g., aripiprazole, quetiapine, or lithium).

2. Continuation Phase (6 to 9 Months Post-Remission)

• Clinical Standard: Once complete symptom remission is achieved, antidepressant therapy must be continued at the exact same therapeutic dose that induced remission for a minimum of 6 to 9 months.
• Clinical Rationale: Premature discontinuation during this vulnerable neurobiological recovery window results in a relapse rate exceeding 50%.

3. Maintenance Phase (≥ 2 Years to Indefinite)

• Indications for Long-Term Maintenance:
  • History of 3 or more lifetime depressive episodes;
  • High risk of suicide or history of severe, disabling episodes;
  • Persistent residual depressive symptoms;
  • Co-occurring psychiatric or chronic medical comorbidities.

---

Antidepressant Discontinuation Syndrome (ADS)

Abrupt cessation or rapid dose reduction of antidepressants can trigger Antidepressant Discontinuation Syndrome (ADS). Symptoms typically begin within 24 to 72 hours of drug cessation and can cause severe distress.

The FINISH Mnemonic

The clinical features of ADS are organized using the FINISH mnemonic:

                     FINISH MNEMONIC FOR DISCONTINUATION SYNDROME

   F ── Flu-like Symptoms (Fatigue, lethargy, myalgias, arthralgias, headache, diaphoresis, chills)
   I ── Insomnia (Sleep fragmentation, vivid disturbing dreams, terrifying nightmares)
   N ── Nausea (Gastrointestinal cramping, vomiting, diarrhea, anorexia)
   I ── Imbalance (Dizziness, lightheadedness, vertigo, gait ataxia)
   S ── Sensory Disturbances (Paresthesias, electric-shock sensations in head/neck ["brain zaps"])
   H ── Hyperarousal (Severe rebound anxiety, agitation, irritability, aggression, emotional lability)

Pharmacokinetic Risk Stratification

The risk and severity of ADS correlate directly with the drug's elimination half-life and the presence of active metabolites:

• Highest Risk: Paroxetine (t1/2 ~21 hours; potent anticholinergic rebound) and Venlafaxine (t1/2 ~5 hours; desvenlafaxine t1/2 ~11 hours). Both agents have rapid clearance and no ultra-long metabolites.
• Lowest Risk: Fluoxetine (parent drug t1/2 = 2 to 4 days; active metabolite norfluoxetine t1/2 = 7 to 15 days). Fluoxetine inherently self-tapers, making ADS exceptionally rare.

Hyperbolic Tapering Protocol & Management

• Gradual Stepwise Reductions: Antidepressants should be tapered gradually over weeks to months (e.g., reducing the dose by 10% to 25% every 2 to 4 weeks).
• Managing Acute ADS: If severe discontinuation symptoms emerge, immediately reinstate the previous effective dose to achieve symptom resolution, then resume tapering at a much slower, hyperbolic pace. Alternatively, cross-taper to a fluoxetine bridge (10–20 mg) and slowly taper the fluoxetine.

---

Pediatric and Young Adult Suicide Warning

Health Canada's 2004 advisory and current antidepressant monographs warn that patients of all ages may experience behavioural and emotional changes, including self-harm and suicidal thinking, especially early in treatment and after dose changes. The US FDA uses a boxed warning that focuses on children, adolescents and young adults under 25. Both agencies stress close monitoring rather than avoiding treatment.

• Epidemiological Context: Meta-analyses show a small absolute increase in non-fatal suicidal thoughts and gestures (approximately 4% in drug-treated vs. 2% in placebo-treated youth) during the initial 1 to 2 months of therapy. No increase in completed suicides has been demonstrated.
• Clinical Mechanism: Antidepressants often restore physical energy and resolve psychomotor retardation before resolving subjective dysphoria, despair, and hopeless ideation, creating a vulnerable window of active kinetic drive.
• Mandatory Practice Directive: Pharmacists must counsel patients and families to monitor for signs of worsening depression, severe agitation, akathisia, panic, or emerging suicidal ideation, especially during the first 2 to 4 weeks of initiation or following dose titrations. Early follow-up within 7 to 14 days is essential.

---

Generalized Anxiety Disorder (GAD) & Panic Disorder

Generalized Anxiety Disorder (GAD) is characterized by chronic, excessive, uncontrollable worry lasting at least 6 months, accompanied by somatic tension, restlessness, fatigue, and sleep disturbance. Panic disorder involves recurrent, unexpected panic attacks and anticipatory anxiety.

First-Line Pharmacotherapy (CANMAT Anxiety Guidelines)

• SSRIs: Escitalopram, Sertraline, Paroxetine.
• SNRIs: Venlafaxine XR, Duloxetine.
• Pregabalin: Recommended as a first-line non-antidepressant option for GAD under Canadian guidelines (binds alpha-2-delta calcium channel subunit; rapid onset, anxiolytic efficacy without serotonergic sexual dysfunction).

---

Benzodiazepine Stewardship & Deprescribing Protocols

Benzodiazepines (e.g., lorazepam, clonazepam, alprazolam, diazepam) act as positive allosteric modulators at GABA-A receptors, enhancing gamma-aminobutyric acid inhibitory neurotransmission.

Clinical Role: Short-Term Bridging Only

• Appropriate Indication: Short-term management (maximum 2 to 4 weeks) for severe, acute, incapacitating anxiety crises, or as a temporary bridge during the initial 2 to 3 weeks while titrating an SSRI or SNRI.
• Beers Criteria & Long-Term Risks: Long-term use (> 4 weeks) is strongly discouraged. Chronic use causes pharmacodynamic tolerance, physical dependence, cognitive decline, anterograde amnesia, psychomotor impairment, motor vehicle collisions, and a doubled risk of falls and hip fractures in geriatric populations.

Deprescribing & Tapering Schedules

Benzodiazepines must never be stopped abruptly in chronically treated patients. Sudden discontinuation can precipitate severe autonomic rebound, delirium, psychosis, and life-threatening withdrawal seizures (most dangerous with short-acting, high-potency agents like alprazolam and lorazepam).

                        BENZODIAZEPINE TAPERING PRINCIPLES

     STEP 1: STABILIZE                 STEP 2: HYPERBOLIC REDUCTIONS          STEP 3: CONVERT IF NEEDED
┌─────────────────────────────┐       ┌─────────────────────────────┐       ┌─────────────────────────────┐
│ • Establish total daily     │       │ • Reduce dose by 10% to 25% │       │ • If withdrawal emerges on  │
│   dose baseline             │───►   │   every 1 to 2 weeks        │───►   │   short-acting agents,      │
│ • Set realistic timeline    │       │ • Slow taper at tail end    │       │   convert to equivalent     │
│   (2 to 6+ months)          │       │   (last 25% is the hardest) │       │   long-acting Diazepam      │
└─────────────────────────────┘       └─────────────────────────────┘       └─────────────────────────────┘

• Taper Rate: Reduce the daily dose by 10% to 25% every 1 to 2 weeks, slowing the decrement toward the end of the taper (the final 25% of the dose requires the slowest titration).
• Diazepam Substitution Strategy: For patients experiencing interdose rebound withdrawal on short-acting agents (alprazolam, lorazepam), calculate the total daily diazepam equivalent (e.g., Lorazepam 1 mg ≈ Diazepam 10 mg; Clonazepam 0.5 mg ≈ Diazepam 10 mg) and substitute long-acting diazepam in divided doses, facilitating smooth plasma concentrations during extended outpatient tapers.

---

Clinical Case Scenario: Managing Treatment Non-Response and Adverse Effects

A 42-year-old male accountant presents to his community pharmacy with a prescription for venlafaxine XR 150 mg daily. Review of his provincial electronic health record indicates he was diagnosed with MDD 8 weeks ago and has been taking escitalopram 20 mg daily with confirmed adherence. He reports that his PHQ-9 score dropped from 18 to 15 (a 16% reduction, indicating non-response), and he is distressed by persistent delayed ejaculation and anorgasmia. His baseline blood pressure today is 138/86 mmHg.

Clinical Pharmacist Evaluation & Care Plan:

1. Assessment of Non-Response: The patient completed an adequate 8-week trial of escitalopram at maximum therapeutic dosing (20 mg/day). A symptom reduction of < 20% confirms non-response under CANMAT guidelines, fully justifying a class switch.
2. Analysis of the New Agent: Venlafaxine XR is a first-line SNRI. However, at doses ≥ 150 mg/day, venlafaxine stimulates norepinephrine reuptake and can induce dose-dependent blood pressure elevation. Because his baseline BP is high-normal (138/86 mmHg), blood pressure must be monitored at baseline and 2 to 4 weeks post-titration.
3. Addressing Sexual Dysfunction: Switching to venlafaxine XR is unlikely to resolve his sexual dysfunction, as SNRIs block SERT and carry sexual dysfunction rates comparable to SSRIs. The pharmacist consults with the prescriber to suggest Bupropion XL 150 mg daily, titrating to 300 mg daily. Bupropion is an activating NDRI that avoids serotonin-mediated sexual dysfunction, treats fatigue, and provides equivalent antidepressant efficacy without increasing blood pressure to the degree of high-dose SNRIs.